199 related articles for article (PubMed ID: 38531883)
1. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Middha P; Thummalapalli R; Betti MJ; Yao L; Quandt Z; Balaratnam K; Bejan CA; Cardenas E; Falcon CJ; Faleck DM; ; Gubens MA; Huntsman S; Johnson DB; Kachuri L; Khan K; Li M; Lovly CM; Murray MH; Patel D; Werking K; Xu Y; Zhan LJ; Balko JM; Liu G; Aldrich MC; Schoenfeld AJ; Ziv E
Nat Commun; 2024 Mar; 15(1):2568. PubMed ID: 38531883
[TBL] [Abstract][Full Text] [Related]
2. Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Middha P; Thummalapalli R; Betti MJ; Yao L; Quandt Z; Balaratnam K; Bejan CA; Cardenas E; Falcon CJ; Faleck DM; ; Gubens MA; Huntsman S; Johnson DB; Kachuri L; Khan K; Li M; Lovly CM; Murray MH; Patel D; Werking K; Xu Y; Zhan LJ; Balko JM; Liu G; Aldrich MC; Schoenfeld AJ; Ziv E
medRxiv; 2023 Sep; ():. PubMed ID: 37292751
[TBL] [Abstract][Full Text] [Related]
3. Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis.
Kayashima A; Shimozaki K; Hirata K; Mutaguchi M; Takabayashi K; Hayashi Y; Hosoe N; Ogata H; Sujino T; Kanai T
Clin J Gastroenterol; 2021 Feb; 14(1):152-158. PubMed ID: 33058056
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival.
Weingarden AR; Gubatan J; Singh S; Balabanis TC; Patel A; Sharma A; Habtezion A
World J Gastroenterol; 2022 Oct; 28(39):5750-5763. PubMed ID: 36338892
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis.
Hone Lopez S; Kats-Ugurlu G; Renken RJ; Buikema HJ; de Groot MR; Visschedijk MC; Dijkstra G; Jalving M; de Haan JJ
Virchows Arch; 2021 Dec; 479(6):1119-1129. PubMed ID: 34338882
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer.
Machado AP; Shaikh AS; Saji A; Shatila M; Oliva IG; Wang Y; Shirwaikar Thomas A
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791997
[TBL] [Abstract][Full Text] [Related]
7. Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis.
Pisuchpen N; Durbin SM; Mooradian MJ; Fintelmann FJ; Reynolds KL; Dougan M; Kambadakone A
Eur Radiol; 2021 Dec; 31(12):8868-8878. PubMed ID: 34081152
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Associations between NRAMP1 Polymorphisms and Susceptibility to Ulcerative Colitis/Crohn's Disease: A Meta-Analysis.
Sun M; Zhang L; Shi S
Immunol Invest; 2016; 45(3):255-70. PubMed ID: 27019053
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of the relationship between MYO9B gene polymorphisms and susceptibility to Crohn's disease and ulcerative colitis.
Li P; Yang XK; Wang X; Zhao MQ; Zhang C; Tao SS; Zhao W; Huang Q; Li LJ; Pan HF; Ye DQ
Hum Immunol; 2016 Oct; 77(10):990-996. PubMed ID: 27435931
[TBL] [Abstract][Full Text] [Related]
12. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study.
Cleynen I; Boucher G; Jostins L; Schumm LP; Zeissig S; Ahmad T; Andersen V; Andrews JM; Annese V; Brand S; Brant SR; Cho JH; Daly MJ; Dubinsky M; Duerr RH; Ferguson LR; Franke A; Gearry RB; Goyette P; Hakonarson H; Halfvarson J; Hov JR; Huang H; Kennedy NA; Kupcinskas L; Lawrance IC; Lee JC; Satsangi J; Schreiber S; Théâtre E; van der Meulen-de Jong AE; Weersma RK; Wilson DC; ; Parkes M; Vermeire S; Rioux JD; Mansfield J; Silverberg MS; Radford-Smith G; McGovern DP; Barrett JC; Lees CW
Lancet; 2016 Jan; 387(10014):156-67. PubMed ID: 26490195
[TBL] [Abstract][Full Text] [Related]
13. New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis.
Velikova T; Krastev B; Gulinac M; Zashev M; Graklanov V; Peruhova M
World J Clin Cases; 2024 Feb; 12(6):1050-1062. PubMed ID: 38464930
[TBL] [Abstract][Full Text] [Related]
14. Genetic association between IL23R rs11209026 and rs10889677 polymorphisms and risk of Crohn's disease and ulcerative colitis: evidence from 41 studies.
Zhu Y; Jiang H; Chen Z; Lu B; Li J; Shen X
Inflamm Res; 2020 Jan; 69(1):87-103. PubMed ID: 31728561
[TBL] [Abstract][Full Text] [Related]
15. Collagenous Colitis Is Associated With HLA Signature and Shares Genetic Risks With Other Immune-Mediated Diseases.
Stahl E; Roda G; Dobbyn A; Hu J; Zhang Z; Westerlind H; Bonfiglio F; Raj T; Torres J; Chen A; Petras R; Pardi DS; Iuga AC; Levi GS; Cao W; Jain P; Rieder F; Gordon IO; Cho JH; D'Amato M; Harpaz N; Hao K; Colombel JF; Peter I
Gastroenterology; 2020 Aug; 159(2):549-561.e8. PubMed ID: 32371109
[TBL] [Abstract][Full Text] [Related]
16. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis.
Halsey TM; Thomas AS; Hayase T; Ma W; Abu-Sbeih H; Sun B; Parra ER; Jiang ZD; DuPont HL; Sanchez C; El-Himri R; Brown A; Flores I; McDaniel L; Ortega Turrubiates M; Hensel M; Pham D; Watowich SS; Hayase E; Chang CC; Jenq RR; Wang Y
Sci Transl Med; 2023 Jun; 15(700):eabq4006. PubMed ID: 37315113
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis.
Westdorp H; Sweep MWD; Gorris MAJ; Hoentjen F; Boers-Sonderen MJ; van der Post RS; van den Heuvel MM; Piet B; Boleij A; Bloemendal HJ; de Vries IJM
Front Immunol; 2021; 12():768957. PubMed ID: 34777387
[TBL] [Abstract][Full Text] [Related]
18. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
19. Associations between TNFSF15 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: A meta-analysis.
Zhang J; Zhang J; Wu D; Wang J; Dong W
Autoimmunity; 2014 Dec; 47(8):512-8. PubMed ID: 25028192
[TBL] [Abstract][Full Text] [Related]
20. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis.
Abu-Sbeih H; Ali FS; Wang X; Mallepally N; Chen E; Altan M; Bresalier RS; Charabaty A; Dadu R; Jazaeri A; Lashner B; Wang Y
J Immunother Cancer; 2019 Apr; 7(1):93. PubMed ID: 30940209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
